Groupe Hospitalier Public Du Sud De L Oise
- Address
- Boulevard Laennec, 60100 Creil, France
Groupe Hospitalier Public Du De L'Oise - Oncology Research Center
The Groupe Hospitalier Public Du De L'Oise is a prominent public healthcare institution specializing in advanced oncology research and treatment. The center demonstrates significant expertise across multiple cancer types, with a strong focus on precision medicine approaches and innovative therapeutic combinations. Their research portfolio encompasses both solid tumors and advanced metastatic diseases, incorporating cutting-edge immunotherapy, targeted therapy, and personalized treatment strategies.
- Breast cancer research including HER2-positive early breast cancer and hormone receptor-positive metastatic disease with novel drug combinations
- Gastrointestinal malignancies including colon carcinoma with ctDNA-guided adjuvant therapy and metastatic colorectal cancer treatment optimization
- Thoracic oncology focusing on oligometastatic non-small cell lung cancer with immunotherapy-based approaches and local ablative treatments
- Gynecologic oncology and genitourinary cancers including MMR deficient endometrial cancer and advanced clear-cell renal carcinoma
The center is particularly committed to biomarker-driven clinical trials and digital health innovations, including FGFR alterations in solid tumors and patient-reported outcomes monitoring. Their participation in national cooperative group trials (PRODIGE, GINECO-ENGOT) underscores their role in shaping evidence-based cancer care in France. The institution emphasizes both disease-free survival improvement and quality of life optimization through real-world evidence generation and adaptive treatment strategies.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 5 therapeutic areas and 15 of 28 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 6 by active trials.
lock +5 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
lock +1 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 978 other sites in France
Therapeutic Area Benchmark — France
Select a therapeutic area to compare against other sites in France.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: France
Market Share
Country: France
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Groupe Hospitalier Public Du Sud De L Oise
lock Showing 1 of 10 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| Evaluation of Circulating Tumor DNA-Guided Adjuvant Therapy with Fluorouracil, Folinic Acid, and Oxaliplatin in Stage II Colon Carcinoma | Centre Hospitalier Universitaire De Dijon | Phase III | Recruiting | Aug 2024 | — |
IMP list
lock Showing 1 of 28 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Fluorouracil | 4 | Unknown | 2014-12-23 | 2026-02-19 |
Request feasibility information
Ask this centre about capacity, equipment and patient population.
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.